Article Text

Download PDFPDF
Immunohistochemical Analysis for Therapeutic Targets and Prognostic Markers in Low-Grade Endometrial Stromal Sarcoma
  1. Jeong-Yeol Park, MD, PhD*,
  2. Kyu-Rae Kim, MD, PhD and
  3. Joo-Hyun Nam, MD, PhD*
  1. *Departments of Obstetrics and Gynecology, and
  2. Pathology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
  1. Address correspondence and reprint requests to Joo-Hyun Nam, MD, PhD, Department of Obstetrics and Gynecology, University of Ulsan, College of Medicine, Asan Medical Center, #388-1, Poong-nap Dong, Song-pa Gu, Seoul, 138-736, Korea. E-mail: jhnam{at}amc.seoul.kr.

Abstract

Objective To investigate potential therapeutic targets and prognostic markers for low-grade endometrial stromal sarcoma (LGESS).

Materials and Methods Thirty-nine patients with LGESS were included in this study. Using tissue microarrays, the immunohistochemical expression levels of 5 therapeutic targets (epidermal growth factor receptor, human epidermal growth factor 2, vascular endothelial growth factor receptor, platelet-derived growth factor receptor [PDGFR], and c-kit) and 3 proteins involved in cell proliferation (p16, p53, and ki67) were investigated. The associations between these targets, markers, other clinicopathological factors, disease-free survival (DFS), and overall survival (OS) were analyzed.

Results Epidermal growth factor receptor and human epidermal growth factor 2 were not expressed in these 39 patients. Vascular endothelial growth factor receptor, PDGFR, c-kit, p16, p53, and ki67 were expressed in 10 (25.6%), 28 (71.8%), 32 (82.1%), 18 (46.2%), 4 (10.3%), and 21 (53.8%) patients, respectively. The expression of each marker was not significantly associated with other clinicopathological factors. On multivariate analysis, p53 and ki67 were associated with significantly poorer DFS and OS. The 5-year DFS rates were 88%, 46%, and 0% for the p53(−)/ki67(−) group (n = 18), p53(−)/ki67(+) group (n = 17), and p53(+)/ki67(+) group (n = 4) (P = 0.002), respectively; the 5-year OS rates were 100%, 71%, and 0%, respectively (P < 0.001). The time to recurrence was longer (P = 0.123), and more patients had distant recurrence in the p53(+)/ki67(+) group (P = 0.063).

Conclusions In patients with LGESS, c-kit and PDGFR were expressed in higher portions of patients, suggesting that imatinib mesylate should be investigated as a potential targeting agent. Both p53 and ki67 demonstrated strong prognostic implications, suggesting that further evaluation using these markers is required.

  • Low-grade endometrial stromal sarcoma
  • PDGFR
  • c-kit
  • p53
  • ki67

Statistics from Altmetric.com

Footnotes

  • This study was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Korea (grant no. A091279).

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.